Drugs / MuGard
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02015559 | Oct 2014 → Nov 2018 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, mouth disorder +1 | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MuGard | “Evaluate whether use of prophylactic MuGard (mucoadhesive oral wound rinse) in participants being treated with everolimus will reduce the rate of stomatitis.” NCT02015559 ↗ |
| Route | Oral | “Given PO” NCT02015559 ↗ |